Skip to content

What Is The Future Of U.S. Orphan Drug Development ?

December 23, 2012

What is the future of orphan drug development in the United States ? This is a question many professionals in the field are now asking. A very interesting short article with the following citation (FREE download of article) :

Woodcock J. The Future of Orphan Drug Development. Clinical Pharmacology & Therapeutics. August 2012;92(2):146-148.

Some interesting points are made by this article:

– Almost 400 approved orphan drugs in the U.S.

– Proportion of new molecular entities (NMEs) that reach market using a rare disease indication is growing

– In 2011, the proportion of NMEs approved using a rare disease indication is 37%

– Larger pharmaceutical companies are increasing their involvement in development of drugs for rare diseases

– With the increase in genomics and personalized medicine, “drug development will focus on targeting specific subsets of patients with a particular disease and that are likely candidates for orphan drug status”.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: